GARDASIL 9 30 µg/0.5 mL+ 40 µg/0.5 mL+ 60 µg/0.5 mL+ 40 µg/0.5 mL+ 20 µg/0.5 mL+ 20 µg/0.5 mL+ 20 µg/0.5 mL+ 20 µg/0.5 mL+ 20 µg Bosnia y Herzegovina - croata - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gardasil 9 30 µg/0.5 ml+ 40 µg/0.5 ml+ 60 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml+ 20 µg/0.5 ml+ 20 µg/0.5 ml+ 20 µg/0.5 ml+ 20 µg

merck sharp & dohme bh d.o.o. - papilomavirus (humani tipovi 6,11,16,18,31,33,45,52,58) - suspenzija za injekciju u napunjenoj šprici - 30 µg/0.5 ml+ 40 µg/0.5 ml+ 60 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml+ 20 µg/0.5 ml+ 20 µg/0.5 ml+ 20 µg/0.5 ml+ 20 µg/0.5 ml - 1 doza (0,5 ml) približno sadrži: humani papilomavirus1 tip 6 l1 protein2, 3 30 mikrograma humani papilomavirus1 tip 11 l1 protein2, 3 40 mikrograma humani papilomavirus1 tip 16 l1 protein2, 3 60 mikrograma humani papilomavirus1 tip 18 l1 protein2, 3 40 mikrograma humani papilomavirus1 tip 31 l1 protein2, 3 20 mikrograma humani papilomavirus1 tip 33 l1 protein2, 3 20 mikrograma humani papilomavirus1 tip 45 l1 protein2, 3 20 mikrograma humani papilomavirus1 tip 52 l1 protein2, 3 20 mikrograma humani papilomavirus1 tip 58 l1 protein2, 3 20 mikrograma

Abrysvo Unión Europea - croata - EMA (European Medicines Agency)

abrysvo

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekcije respiratornih sincicijskih virusa - cjepiva - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. pogledajte odjeljke 4. 2 i 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Spikevax (previously COVID-19 Vaccine Moderna) Unión Europea - croata - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Ervebo Unión Europea - croata - EMA (European Medicines Agency)

ervebo

merck sharp & dohme b.v.  - рекомбинантный virus везикулярного стоматита (soj indiana) s brisanje koverti glikoprotein, zamijenjen zair ebole (soj киквите 1995) površinski glikoprotein - Геморрагическая groznice ebole - cjepiva - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. korištenje ervebo moraju biti u skladu sa službenim preporukama.

Zabdeno Unión Europea - croata - EMA (European Medicines Agency)

zabdeno

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Геморрагическая groznice ebole - cjepiva - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Rabipur prašak i otapalo za otopinu za injekciju u napunjenoj štrcaljki, cjepivo protiv bjesnoće, inaktivirano Croacia - croata - HALMED (Agencija za lijekove i medicinske proizvode)

rabipur prašak i otapalo za otopinu za injekciju u napunjenoj štrcaljki, cjepivo protiv bjesnoće, inaktivirano

bavarian nordic a/s, philip heymans allé 3, hellerup, danska - virus bjesnoće, soj flury lep (inaktiviran) - prašak i otapalo za otopinu za injekciju u napunjenoj štrcaljki - 1 doza = 1 ml - urbroj: 1 bočica (1,0 ml) nakon rekonstitucije sadrži: virus bjesnoće (inaktivirani, soj flury lep) ≥ 2,5 internacionalne jedinice (iu), proizveden na pročišćenim stanicama pilećih embrija (pcec)

PRIORIXTETRA 3 Log10CCID50/0.5 mL+ 4,4 Log10CCID50/0.5 mL+ 3 Log10CCID50/0.5 mL+ 3,3 Log10PFU/0.5 mL prašak i rastvarač za rastv Bosnia y Herzegovina - croata - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

priorixtetra 3 log10ccid50/0.5 ml+ 4,4 log10ccid50/0.5 ml+ 3 log10ccid50/0.5 ml+ 3,3 log10pfu/0.5 ml prašak i rastvarač za rastv

glaxosmithkline d.o.o.sarajevo - kombinovana пропорциональному protiv morbila, parotitisa, rubeole sam varičela, ziva, atenuisana - prašak i rastvarač za rastvor za injekciju u napunjenom injekcionom špricu - 3 log10ccid50/0.5 ml+ 4,4 log10ccid50/0.5 ml+ 3 log10ccid50/0.5 ml+ 3,3 log10pfu/0.5 ml - 0,5 ml rastvora za injekciju sadrži: 3,0 log ccid50 živog atenuisanog virusa morbila (schwarz soj); 4,4 log ccid50 živog atenuisanog virusa parotitisa (rit 4385 soj, dobiven iz soja jeryl lynn)); 3,0 log ccid50 živog atenuisanog virusa rubele (wistar ra 27/3 soj); 3,3 log pfu živog atenuisanog virusa varičela (soj oka)